News Celgene scores at ASH18 with double luspatercept data A pair of clinical trial wins for Celgene’s luspatercept at the American Society of Haematology (ASH) meeting have set up a filing for the new drug in mid-2019.
News Spark reassures on safety of haemophilia gene therapy Study of nine patients produce encouraging results
News As rituximab biosimilars close in, Roche showcases Gazyva su... Roche faces competition against its blockbuster haematology drug
News CAR-Ts to take centre stage at ASH haematology congress Haematology is one of the most exciting areas in drug development today, with waves of new treatments emerging for hard-to-treat diseases.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.